egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
Published 8 years ago • 187 plays • Length 18:06Download video MP4
Download video MP3
Similar videos
-
20:24
targeted treatment with egfr tkis: front line options
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
13:26
debate: drug of choice for exon 19 del egfr mutant nsclc - any egfr tki
-
20:35
tki-resistant egfr-mutant nsclc
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
22:26
what's your approach? treating myelofibrosis
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
4:09
frontline afatinib in egfr-mutant nsclc
-
21:35
long term management of egfr-mutant nsclc -tsao
-
4:59
egfr therapy in nsclc
-
27:37
next generation egfr inhibitors for mutations and disease
-
3:24
sequencing of therapies in egfr-mutant nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
5:28
egfr-mutated nsclc; where we are now?
-
10:45
debate: adjuvant egfr-directed therapy for patients with early stage nsclc? - no